| vildagliptin / Generic mfg. |
ACTRN12610001104044: Effects of dipeptidyl peptidase IV (DPP-IV) inhibition (vildagliptin) on plasma concentrations of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) during intraduodenal fat infusion. |
|
|
| Not yet recruiting | 4 | 16 | | | Royal Adelaide Hospital, Novartis Pharmaceuticals Australia Pty. Ltd. | Physiological study to investigate the effects of intraduodenal fat in healthy volunteers.
Outcomes may have implications for type 2 diabetes and obesity. | | | | |
ACTRN12612001005842: Does the drug Galvus enhance the effects of a protein preload to reduce blood glucose concentrations after a meal? |
|
|
| Not yet recruiting | 4 | 22 | | | Professor Michael Horowitz, Novartis Pharmaceuticals Australia Pty. Ltd. | Type 2 diabetes | | | | |
ACTRN12613000224729: The efficacy and tolerability of Galvus (Vildagliptin) compared to Sulfonylureas in patients with new onset diabetes after transplantation (NODAT) |
|
|
| Not yet recruiting | 4 | 48 | | | Sydney Local Health District, Novartis Pharmaceuticals Pty Ltd | New onset diabetes after transplant, Renal Transplant | | | | |
ACTRN12613000418774: Effects of Galvus (Vildagliptin) on Markers of Inflammation in Diabetic Foot Ulcer: A prospective, randomized, double-blind, placebo-controlled pilot study |
|
|
| Recruiting | 4 | 50 | | | Assoc. Professor Usman H. Malabu; FRCPI, FRACP., Novartis Pharmaceuticals | Type 2 Diabetes
Diabetic Foot Ulcer, Anti-inflammatory effects of Vildagliptin, Diabetic foot ulcer healing properties of Vildagliptin | | | | |
ACTRN12614001117606: The role of glucagon-like peptide-1 (GLP-1) in glycaemic, triglyceride and energy expenditure responses to fat in type 2 diabetes. |
|
|
| Recruiting | 4 | 20 | | | Dr Tanya Little, Novartis Pharmaceuticals Australia Pty. Ltd. | Type 2 diabetes | | | | |
2008-004231-38: Effects of vildagliptin (Galvus®) on beta-cell function and turnover in humans |
|
|
| Ongoing | 4 | 40 | Europe | Tablet, Galvus | Department of Medicine I, University Hospital St.Josef-Hospital, Ruhr University Bochum | Diabetes mellitus, beta-cell function before and after pancreatic surgery | | | | |
ChiCTR-TRC-12002553: Vildagliptin on glycemic control in newly diagnosed type 2 diabetes in the short-term insulin pump therapy and remission: a prospective, randomized, open, controlled single-center clinical study |
|
|
| Completed | 4 | 60 | | CSII monotherapy ;CSII + Vildagliptin 50mg bid | Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Level of the institution：, Hospital | Diabetes | | | | |
2013-002955-13: Effects of vildaglipitin and glimepiride on variability of glycemic values and cardiovascular risk in diabetic patients is not well controlled with insulin evening Effetti del farmaco vildagliptin e glimepiride sulla variabilità della glicemia e sul rischio cardiovascolare in pazienti diabetici non ben controllati con l’insulina serale |
|
|
| Ongoing | 4 | 68 | Europe | Tablet, Galvus, Amaryl | AFAR, AFAR | type 2 diabetes type 2 diabetes in failure with basal insulin, type 2 diabetes not controlled with insulin diabete di tipo 2 non ben controllato con insulina, Diseases [C] - Hormonal diseases [C19] | | | | |
| Ongoing | 4 | 14 | Europe | Chewable tablet, Galvus | KULeuven, KULeuven | healthy volunteers no medical condition, drug will be studied because they are known to influence gastric motility, healthy subjects, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
ChiCTR-TRC-13003858: The study of Dipeptidyl peptidase-IV inhibitor's efficacy and safety when it is applied on type 2 diabetes whose blood suger was poorly controlled with original oral antidiabetic drug |
|
|
| Completed | 4 | 40 | | saxagliptin vs Vildagliptin | The First Hospital, Guangzhou Medical University; The First Hospital, Guangzhou Medical University, Pharmaceutical Association | Type 2 diabetes mellitus | | | | |
ChiCTR-IPR-15005986: Effects of vildagliptin combined with insulin on the daily acute glucose fluctuations by continuous subcutaneous glucose monitoring in patients with type 1 diabetes compared with conventional insulin therapy |
|
|
| Recruiting | 4 | 44 | | vildagliptin 50mg bid+conventional intensive insulin therepy ;conventional insulin therapy | Shenzhen People's Hospital; Shenzhen People's Hospital, self- financing | type 1 diabetes | | | | |
2007-001049-16: A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes. |
|
|
| Ongoing | 4 | 438 | Europe | Vildagliptin, LAF237A, | Novartis Pharmaceuticals UK Ltd | Type 2 Diabetes | | | | |
2010-019346-11: Effects of vildagliptin twice daily vs. sitagliptin once daily on reduction of oxidative stress and inflammation by blunting interprandial acute glucose fluctuations in patients with type 2 diabetes - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) Effetti di vildagliptin(50 mg x 2/die) vs sitagliptin (100 mg/die) sullo stress ossidativo e sull\'infiammazione in relazione alle fluttuazioni glicemiche interprandiali in pazienti con diabete mellito tipo 2 - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) |
|
|
| Ongoing | 4 | 90 | Europe | Tablet | AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA\' DEGLI STUDI DI NAPOLI | patients with type 2 diabetes poorly controlled PAZIENTI DIABETICI SCOMPENSATI | | | | |
| Ongoing | 4 | 20 | Europe | Vildagliptin, Galvus | Erasmus Medical Center, Novartis Europharma Ltd. | impaired fasting glucose/impaired glucose tolerance, prediabetes | | | | |
ChiCTR2000040826: A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment |
|
|
| Completed | 4 | 90 | | Acarbose tablets orally (100 mg/tablet, Bayer, Leverkusen, Germany) 3 times each day with 100 mg each time ;vildagliptin tablets orally (50 mg/tablet, AstraZeneca, Cambridge, London, England) 2 times each day with 50 mg each time ;saxagliptin tablets orally (5 mg/tablet, AstraZeneca, Cambridge, London, England) one time each day with 5 mg each time | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Self-financing | Type 2 diabetes mellitus | | | | |
ChiCTR-OIN-16009294: A comparative study of vildagliptin and other OAD in patients with T2DM inadequately controlled with current therapy |
|
|
| Not yet recruiting | 4 | 200 | | vildagliptin 50mg qd or 50mg bid ;any OAD | The Second affiliated hospital of Fujian Medical University; The Second affiliated hospital of Fujian Medical University, self-financing | type 2 diabetes | | | | |
2013-004737-33: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM Etude prospective randomisée multicentrique d’évaluation de la VILDagliptine associée à l’insuline sur le contrôle glycémique chez les patients hémoDIALysés diabétiques de type 2 : étude VILDDIAL |
|
|
| Not yet recruiting | 4 | 70 | Europe | Vildagliptine, Tablet, Solution for injection, Suspension for injection, Galvus, LANTUS 100 unités/ml solution injectable, LANTUS 100 unités/ml solution injectable en cartouche, LANTUS 100 unités/ml solution injectable en cartouche pour OptiClik, Lantus OptiSet 100 unités/ml solution injectable en stylo prérempli, Lantus SoloStar 100 unités/ml solution injectable en stylo prérempli, Levemir 100 U/ml, solution injectable en cartouche, Levemir 100 U/ml, solution injectable en stylo prérempli, Levemir InnoLet 100 U/ml, solution injectable en stylo prérempli, Levemir FlexTouch 100 U/ml, solution injectable en stylo prérempli, Apidra 100 unités/ml solution injectable en flacon, Apidra 100 unités/ml solution injectable en cartouche, Apidra 100 unités/ml solution injectable en cartouche pour OptiClik, Apidra 100 unités/ml solution injectable en stylo prérempli, Apidra SoloStar 100 unités/ml solution injectable en stylo prérempli, Humalog 100 UI/ml, solution injectable en flacon, Humalog 100 UI/ml, solution injectable en cartouche, Humalog Mix25 100 UI/ml suspension injectable en flacon, Humalog Mix25 100 UI/ml suspension injectable en cartouche, Humalog Mix50 100 UI/ml suspension injectable en flacon, Humalog Mix50 100 UI/ml suspension injectable en cartouche, Humalog BASAL 100 UI/ml suspension injectable en cartouche, Humalog Pen 100 UI/ml, solution injectable, Humalog Mix25 100 UI/ml Pen, suspension injectable, Humalog Mix50 100 UI/ml Pen, suspension injectable, Humalog BASAL 100 UI/ml Pen, suspension injectable, Humalog 100 UI/ml KwikPen, solution injectable, Humalog Mix25 100 UI/ml KwikPen, suspension injectable, Humalog Mix50 100 UI/ml KwikPen, suspension injectable, Humalog BASAL 100 UI/ml KwikPen, suspension injectable, NovoRapid 100 U/ml, solution injectable, NovoRapid Penfill 100 U/ml, solution injectable en cartouche, NovoRapid FlexPen 100 U/ml, solution injectable en stylo prérempli, NovoRapid InnoLet 100 U/ml, solution injectable en stylo prérempli, NovoRapid FlexTouch 100 U/ml, solution injectable en stylo prérempli | Hôpitaux Universitaires de Strasbourg, HÔPITAUX UNIVERSITAIRES DE STRASBOURG, NOVARTIS PHARMASAS | haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04485845: Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression |
|
|
| Recruiting | 4 | 39 | RoW | Vildagliptin, Captopril Tablets, MetFORMIN 500 Mg Oral Tablet | Cairo University | Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency | 08/20 | 09/20 | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
2014-001205-41: VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction - VIPER–AMI trial Avaliação da vildagliptina enquanto agente protetor do miocárdio noenfarte agudo do miocárdio. |
|
|
| Ongoing | 3 | 128 | Europe | Galvus, Tablet, Galvus | Sociedade Portuguesa de Cardiologia, Novartis Farma - Produtos Farmacêuticos SA | ST Elevation Myocardial Infarction, Acute Myocardial Infarction, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2004-002466-38: A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%.52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. |
|
|
| Ongoing | 3 | 20 | Europe | not established, Actos, LAF 237, 18/270/01-C, not extablished, Actos, not extablished, Actos | Novartis Pharma AG | Diabetes mellitus | | | | |
2006-005969-18: Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos para demostrar el efecto de 12 semanas de tratamiento con una combinación inicial 100 mg de Vildagliptina qd y 1.000 mg de metformina bid comparado con 1.000 mg de metformina bid en pacientes naïve con Diabetes Tipo 2 |
|
|
| | 3 | 30 | Europe | Vildagliptin, metformin, LAF237A, Metformine, Metformine | Novartis Farmacéutica, S.A., Novartis Pharma Services AG | Diabetes Type II | | 01/08 | | |
2007-003370-26: A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man |
|
|
| Ongoing | 3 | 40 | Europe | Vildagliptin, | Charite Universitätsmedizin Berlin | This is a single center, randomized, double-blind pilot study on patients with Type 2 diabetes. The purpose of this study is to test the effects of vildagliptin (as add-on to metformin) on hepatic insulin clearance, on levels of adipocytokines, metabolic syndrome biomarkers and adipose tissue mRNA expression. | | | | |
2016-002023-28: Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period. |
|
|
| Not yet recruiting | 3 | 186 | Europe | Galvus, inhibiteur dipeptidylpeptidase 4 (DPP-4), Cachet, Galvus, Vildagliptin | CHU Besançon, DGOS | Transplanté rénal à haut risque de développer un diabète de novo Transplanté rénal à haut risque de développer un diabète de novo, Transplanté rénal à haut risque de développer un diabète de novo Transplanté rénal à haut risque de développer un diabète de novo, Body processes [G] - Metabolic Phenomena [G03] | | | | |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT02849899: Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period |
|
|
| Recruiting | 3 | 186 | Europe | Vildagliptin, Galvus, Placebo, Excipient | Centre Hospitalier Universitaire de Besancon, University Hospital, Tours, University Hospital, Lille, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, Amiens University Hospital, University Hospital, Brest, Rennes University Hospital, Tenon Hospital, Paris, Centre Hospitalier Universitaire de Nice, University Hospital, Strasbourg, France | Disorder Related to Renal Transplantation, Diabetes | 07/24 | 12/24 | | |
NCT06142656: Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome |
|
|
| Recruiting | 2/3 | 60 | RoW | Metformin Hydrochloride tablet, Vildagliptin 50 MG | October 6 University | Poly Cystic Ovary Syndrome | 04/24 | 05/24 | | |
2009-014405-14: Vildagliptin in New Onset Diabetes After Transplantation (ViNODAT). A double-blind, randomized, placebo-controlled trial |
|
|
| Ongoing | 2 | | Europe | NOVARTIS EUROPHARM LTD / GB, Galvus ®, Galvus ® | Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse | new onset diabetes mellitus after transplantation | | | | |
METALLICA, NCT04300790: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients |
|
|
| Active, not recruiting | 2 | 69 | Europe | Alpelisib, BYL719, Metformin, Fulvestrant, Letrozole, Exemestane, Vildagliptin, Tamoxifen | MedSIR, Novartis | Breast Cancer | 03/25 | 06/26 | | |
NCT04761861: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia |
|
|
| Recruiting | 2 | 150 | RoW | Vildagliptin 50 MG, Placebo | Sadat City University | Schizophrenia, Dyslipidemias | 12/25 | 12/25 | | |
2017-000899-28: A clinical trial evaluating vildagliptin and nilotinib as a combination treatment to achieve and succesfully maintain treatment free remission in patients with chronic myeloid leukemia. Een klinisch onderzoek naar vildagliptine en nilotinib als combinatiebehandeling voor het bereiken en handhaven van behandelingsvrije remissie bij patiënten met chronische myeloïde leukemie. |
|
|
| Ongoing | 1/2 | 20 | Europe | Nilotinib, Vildaglipitin, AMN107, Capsule, Tablet, Tasigna, Galvus | Albert Schweitzer Hospital, Albert Schweitzer Hospital | Chronic myeloid leukemia Chronische myeloïde leukemie, Chronic myeloid leukemia is a disease of the stem cells in the bone marrow. The abnormal stem cell multiplies and mature and develop into near-normal white cells . Chronische myeloïde leukemie is een ziekte van stamcellen in het beenmerg. De kern van een stamcel is beschadigd geraakt en dat zorgt ervoor dat witte bloedcellen in het beenmerg zich te snel delen., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT04410341: The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients |
|
|
| Active, not recruiting | 1/2 | 100 | RoW | Vildagliptin 50 MG, Escitalopram 20 mg | Sadat City University | Major Depressive Disorder | 12/24 | 12/24 | | |
ChiCTR2200067133: A randomized, open, single-dose, two-cycle, two-sequence, double-crossed fasting and postpranal bioequivalence test of vildagliptin tablets in healthy subjects |
|
|
| Recruiting | 1 | 56 | | In the fasting state, the reference preparation was taken orally in the first cycle, and the test preparation was taken in the second cycle, with a cleaning period of 3 days. ;In the fasting state, the test preparation was taken orally in the first cycle, and the reference preparation was taken in the second cycle, with a cleaning period of 3 days. ;In the fed state, the reference preparation was taken orally in the first cycle, and the test preparation was taken in the second cycle, with a cleaning period of 3 days. ;In the fed state, the test preparation was taken orally in the first cycle, and the reference preparation was taken in the second cycle, with a cleaning period of 3 days. | Huzhou Central Hospital; Huzhou Central Hospital, Sponsor (Zhejiang Huahai Pharmaceutical Co., Ltd.) | healthy subjects | | | | |
ChiCTR-IOR-15006941: Comparative Study on the Influence on Blood Glucose Fluctuation of DPP-4 Inhibitor or Acarbose for T2DM Patients with Inadequately Controlled with insulin |
|
|
| Recruiting | N/A | 100 | | add on vildagliptin 50mg bid ;add on acarbose 50mg tid | The second people's hospital of Shenzhen; Shenzhen 2nd People's Hospital, self-financing | Type 2 Diabetes mellitus | | | | |
| Active, not recruiting | N/A | 120 | RoW | Metformin, Liraglutide, empagliflozin, Vildagliptin | Alexandria University, Eva Pharma | Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2 | 09/21 | 09/22 | | |
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. |
|
|
| Terminated | N/A | 5 | Europe | Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®). | Erasme University Hospital | Type 2 Diabetes, Incretinomimetics, Pancreas | 02/23 | 02/23 | | |
NCT06313008: Empagliflozin Versus Vildagliptin in CAD Patients With T2DM |
|
|
| Recruiting | N/A | 120 | RoW | Empagliflozin 10 MG, Empa, Vildagliptin 50 MG, Vilda | Damanhour University, Tanta University | Coronary Artery Disease, Type 2 Diabetes | 09/24 | 09/24 | | |
NCT06068686: Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 70 | RoW | Vildagliptin 50 MG, Vildagliptin, Glimepiride 3 Mg Oral Tablet, Amaryl | Damanhour University | Type 2 Diabetes | 11/24 | 12/24 | | |
NCT05347459: Cognitive Protective Effect of Newer Antidiabetic Drugs |
|
|
| Recruiting | N/A | 100 | RoW | Dapagliflozin, Empagliflozin, Canagliflozin, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin | Alexandria University | Type 2 Diabetes | 12/23 | 12/23 | | |
NCT05429554: The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients |
|
|
| Recruiting | N/A | 60 | RoW | Vildagliptin | MTI University, National Institute of Diabetes and Endocrinology, Egypt | Type 2 Diabetes Mellitus | 09/22 | 09/22 | | |